Targeting Wnt signaling with Signalomics in primary breast cancer and gynecological pathologies
This study demonstrates that Signalomics can rapidly assess Wnt signaling activation in primary breast and gynecological samples to correlate with disease progression and identify patients who may benefit from targeted Wnt inhibition, marking the first application of this technology in daily clinical settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the human body, cells communicate constantly, passing messages that tell them when to grow, when to stop, and when to divide. One of the most important messengers in this system is a signaling pathway known as Wnt. Think of this pathway as a master switch that controls cell proliferation; when it works correctly, it helps tissues repair and develop. However, when this switch gets stuck in the "on" position, it can drive uncontrolled growth, leading to tumors. This problem is particularly common in diseases affecting the breast, ovaries, and uterus, as well as in a painful condition called endometriosis, where tissue similar to the lining of the womb grows in the wrong places. For decades, doctors have tried to understand these diseases by looking at the DNA inside cells, hoping to find the specific genetic errors that cause the Wnt switch to malfunction. Yet, a patient's genetic code does not always tell the whole story. Sometimes, the DNA looks normal, but the cell's behavior is still chaotic because the signaling network itself has been altered by other factors, such as the environment surrounding the cell or changes in how genes are turned on and off.
A team of researchers, led by scientists from the National Medical Research Center for Obstetrics, Gynecology and Perinatology in Moscow and the University of Geneva, decided to look directly at the activity of these signals rather than just the genetic blueprint. They used a new approach called Signalomics, which acts like a functional test drive for a patient's own cells. Instead of guessing how a pathway might behave based on DNA sequences, this method takes living cells from a patient's tumor or tissue sample and measures exactly how much the Wnt pathway is active at that moment. The researchers collected fresh tissue from patients with breast cancer, ovarian cancer, endometrial cancer, and endometriosis. They isolated the living cells and introduced a special reporter system that lights up when the Wnt pathway is turned on. This allowed them to see two things: how active the pathway was naturally, and how much it could be pushed to become active if the cells were given a specific chemical boost.
The results revealed a striking diversity in how these diseases behave. In breast and ovarian cancers, the Wnt pathway was often quiet in its natural state, barely flickering. However, when the researchers applied the chemical boost, many of these cells showed a massive surge in activity, suggesting that the cells had the hidden potential to turn the pathway on at critical moments. In contrast, endometrial cancer told a different story. About half of the endometrial tumor samples were already running hot, with high levels of Wnt activity even without any chemical help. The researchers also found that the more aggressive the tumor, the higher the Wnt activity tended to be. For endometrial cancer, higher activity levels correlated with more advanced disease stages. In breast cancer, the ability of the cells to ramp up their Wnt signaling when stimulated was linked to more aggressive tumors. Interestingly, in ovarian cancer, the relationship was reversed, with higher stimulated activity appearing in less advanced cases, hinting that this pathway might play different roles at different stages of the disease.
To confirm that these measurements were accurate, the team compared their new method with a standard laboratory technique that looks for the Wnt protein inside the cell nucleus under a microscope. They found a strong agreement between the two, proving that their new functional test was a reliable way to measure what was happening inside the cells. The study went a step further by testing whether blocking this pathway could stop the cells from growing. They treated the patient-derived cells with two different drugs known to inhibit the Wnt signal. One drug, ICG-001, successfully stopped the growth of three-quarters of the samples tested. Another drug, clofazimine, which is already approved for treating leprosy and tuberculosis, worked on a smaller group of samples. This suggests that while the Wnt pathway is a key driver in many of these diseases, not every patient's tumor relies on it in the same way.
The researchers also applied this method to endometriosis, a condition where tissue grows outside the uterus and can invade nearby organs. They found that the Wnt pathway was more active in samples taken from lesions that had invaded the gut or rectum compared to those found in ovarian cysts. This indicates that as the disease becomes more invasive, the cells rely more heavily on this signaling pathway. The study concludes that measuring the actual activity of these signals in a patient's own cells offers a powerful new way to understand the disease. By identifying which patients have tumors that are highly dependent on the Wnt pathway, doctors could potentially select the right targeted therapies for them, moving beyond a one-size-fits-all approach. This work represents the first time this type of functional testing has been applied in a clinical setting for these specific diseases, offering a glimpse into a future where treatment decisions are guided by the real-time behavior of a patient's cells rather than just their static genetic code.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.